Eli Lillys Zepbound Sales Surge to 25th in Market Activity as Single-Dose Vials Launch

On June 16, 2025, Eli Lilly & Co. (LLY) experienced a trading volume of 22.93 billion, ranking 25th in the day's stock market activity. The company's stock price decreased by 1.44%.

Eli Lilly & Co. has announced that all approved doses of its weight loss therapy, Zepbound, will be available in single-dose vials through its direct-to-consumer platform, LillyDirect. This move aims to provide patients with more convenient and accessible options for weight management. The company has introduced vials in various doses, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all priced at $499 per month or less, regardless of the dose. This flat pricing structure is designed to make the medication more affordable for patients who choose to self-pay.

Eli Lilly's decision to offer all approved doses of Zepbound through LillyDirect is expected to enhance patient access to the medication. By providing a range of dose options at a fixed price, the company aims to support patients in their weight loss journeys. This initiative underscores Eli Lilly's commitment to improving healthcare outcomes through innovative solutions and patient-centric approaches.